Morgan Stanley Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $75
Benzinga Newsdesk 1 hour ago
Analyst RatingsNewsPrice Target
Morgan Stanley analyst Michael Ulz maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target from $104 to $75.
Morgan Stanley analyst Michael Ulz maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target from $104 to $75.